Human Microbiome Therapeutics Market Size, Share, Trends, Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), By Therapeutic Area, By Indication, By Approach, By Region

Description

List of Tables

The human microbiome therapeutics market size is expected to reach USD 7.89 billion by 2034, according to a new study by Polaris Market Research. The report "Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), By Therapeutic Area, By Indication, By Approach, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Human microbiome therapeutics refers to a class of medical treatments designed to target, restore, or modify the composition and activity of the human microbiome, the diverse community of microorganisms, including bacteria, viruses, fungi, and archaea, that live in and on the human body. These therapeutics aim to harness the beneficial properties of the microbiome to prevent, treat, or manage various diseases. They may involve the use of live biotherapeutic products, microbial consortia, genetically engineered microbes, prebiotics, or postbiotics. The usage of human microbiome therapeutics spans multiple therapeutic areas. In gastroenterology, they are used to treat conditions such as Clostridioides difficile infections, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). In oncology, they can enhance responses to immunotherapy by modulating gut bacteria that influence immune function.

They are being explored for metabolic disorders such as obesity and type 2 diabetes, neurological conditions like autism spectrum disorder and Parkinson's disease, and skin disorders including eczema and acne. Additionally, microbiome-based interventions are being investigated for allergy prevention and women's health issues, such as bacterial vaginosis. These therapeutics can be administered through oral capsules, dietary supplements, fecal microbiota transplantation (FMT), or topical formulations. The field is rapidly evolving due to advances in microbiome sequencing, synthetic biology, and personalized medicine.

Human Microbiome Therapeutics Market Report Highlights

In terms of product, the probiotics segment accounted for a major revenue share in 2024 due to their widespread use in managing gastrointestinal disorders, enhancing immune health, and restoring gut microbiota balance.

Based on application, the digestive and gastrointestinal disorders held the largest revenue share in 2024 due to high global prevalence of conditions such as irritable bowel syndrome, inflammatory bowel disease, Clostridioides difficile infection, and antibiotic-associated diarrhea.

In terms of manufacturing, the clostridium difficile infection segment dominated the revenue share in 2024 due to high recurrence rates, growing antibiotic resistance, and the urgent need for effective alternatives to conventional antimicrobial therapies.

North America human microbiome therapeutics market accounted for 48.15% of global revenue share in 2024. This dominance is attributed to the rising incidences of chronic diseases such as obesity, diabetes, and inflammatory bowel disease (IBD).

The industry in Asia Pacific is projected to grow at the fastest pace in the coming years, owing to increasing healthcare awareness and rising disposable incomes.

A few key players in the global human microbiome therapeutics market include Enterome SA, Ferring Pharmaceuticals, Finch Therapeutics Group Inc., Locus Biosciences Inc., MaaT Pharma, Microbiotica Ltd, Osel Inc., Seres Therapeutics Inc., Synlogic Inc., and Vedanta Biosciences.

Polaris Market Research has segmented the global human microbiome therapeutics market report on the basis of product, therapeutic area, indication, approach, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Probiotics

Prebiotics

Medical Foods

Prescription Drugs

By Therapeutic Area Outlook (Revenue, USD Billion, 2020-2034)

Autoimmune Disorders

Dental Disorders

Digestive and Gastrointestinal Disorders

Dermatological Disorders

Infectious Disease

Metabolic Disorders

Oncology

Others

By Indication Outlook (Revenue, USD Billion, 2020-2034)

Acne Vulgaris

Atopic Dermatitis

Clostridium difficile Infection

Colorectal Cancer

Diabetes

Inflammatory Bowel Disease (IBD)

Lactose Intolerance

Lung Cancer

Non-alcoholic steatohepatitis (NASH)

Obesity

Coeliac Disease

By Approach Outlook (Revenue, USD Billion, 2020-2034)

Small Molecule Therapies

Single Strain Whole Bacteria

Microbial Consortia

Genetically Modified Single Strain Bacteria

Phage Cocktail

Microbial Ecosystems

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Product Code: PM1687

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Human Microbiome Therapeutics Market Insights

4.1. Human Microbiome Therapeutics Market - Market Snapshot
4.2. Human Microbiome Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. High Prevalence of Chronic Diseases
  - 4.2.1.2. Growing Focus on Personalized Medicine
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Lack of Robust Clinical Data and Awareness
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Human Microbiome Therapeutics Market Trends
4.6. Value Chain Analysis

5. Global Human Microbiome Therapeutics Market, by Product

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
5.3. Probiotics
- 5.3.1. Global Human Microbiome Therapeutics Market, by Probiotics, by Region, 2020-2034 (USD Billion)
5.4. Prebiotics
- 5.4.1. Global Human Microbiome Therapeutics Market, by Prebiotics, by Region, 2020-2034 (USD Billion)
5.5. Medical Foods
- 5.5.1. Global Human Microbiome Therapeutics Market, by Medical Foods, by Region, 2020-2034 (USD Billion)
5.6. Prescription Drugs
- 5.6.1. Global Human Microbiome Therapeutics Market, by Prescription Drugs, by Region, 2020-2034 (USD Billion)

6. Global Human Microbiome Therapeutics Market, by Therapeutic Area

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
6.3. Autoimmune Disorders
- 6.3.1. Global Human Microbiome Therapeutics Market, by Autoimmune Disorders, by Region, 2020-2034 (USD Billion)
6.4. Dental Disorders
- 6.4.1. Global Human Microbiome Therapeutics Market, by Dental Disorders, by Region, 2020-2034 (USD Billion)
6.5. Digestive and Gastrointestinal Disorders
- 6.5.1. Global Human Microbiome Therapeutics Market, by Digestive and Gastrointestinal Disorders, by Region, 2020-2034 (USD Billion)
6.6. Dermatological Disorders
- 6.6.1. Global Human Microbiome Therapeutics Market, by Dermatological Disorders, by Region, 2020-2034 (USD Billion)
6.7. Infectious Disease
- 6.7.1. Global Human Microbiome Therapeutics Market, by Infectious Disease, by Region, 2020-2034 (USD Billion)
6.8. Metabolic Disorders
- 6.8.1. Global Human Microbiome Therapeutics Market, by Metabolic Disorders, by Region, 2020-2034 (USD Billion)
6.9. Oncology
- 6.9.1. Global Human Microbiome Therapeutics Market, by Oncology, by Region, 2020-2034 (USD Billion)
6.10. Others
- 6.10.1. Global Human Microbiome Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Human Microbiome Therapeutics Market, by Indication

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
7.3. Acne Vulgaris
- 7.3.1. Global Human Microbiome Therapeutics Market, by Acne Vulgaris, by Region, 2020-2034 (USD Billion)
7.4. Atopic Dermatitis
- 7.4.1. Global Human Microbiome Therapeutics Market, by Atopic Dermatitis, by Region, 2020-2034 (USD Billion)
7.5. Clostridium difficile Infection
- 7.5.1. Global Human Microbiome Therapeutics Market, by Clostridium difficile Infection, by Region, 2020-2034 (USD Billion)
7.6. Colorectal Cancer
- 7.6.1. Global Human Microbiome Therapeutics Market, by Colorectal Cancer, by Region, 2020-2034 (USD Billion)
7.7. Diabetes
- 7.7.1. Global Human Microbiome Therapeutics Market, by Diabetes, by Region, 2020-2034 (USD Billion)
7.8. Inflammatory Bowel Disease (IBD)
- 7.8.1. Global Human Microbiome Therapeutics Market, by Inflammatory Bowel Disease (IBD), by Region, 2020-2034 (USD Billion)
7.9. Lactose Intolerance
- 7.9.1. Global Human Microbiome Therapeutics Market, by Lactose Intolerance, by Region, 2020-2034 (USD Billion)
7.10. Lung Cancer
- 7.10.1. Global Human Microbiome Therapeutics Market, by Lung Cancer, by Region, 2020-2034 (USD Billion)
7.11. Lactose Intolerance
- 7.11.1. Global Human Microbiome Therapeutics Market, by Lactose Intolerance, by Region, 2020-2034 (USD Billion)
7.12. Non-alcoholic steatohepatitis (NASH)
- 7.12.1. Global Human Microbiome Therapeutics Market, by Non-alcoholic steatohepatitis (NASH), by Region, 2020-2034 (USD Billion)
7.13. Obesity
- 7.13.1. Global Human Microbiome Therapeutics Market, by Obesity, by Region, 2020-2034 (USD Billion)
7.14. Coeliac Disease
- 7.14.1. Global Human Microbiome Therapeutics Market, by Coeliac Disease, by Region, 2020-2034 (USD Billion)

8. Global Human Microbiome Therapeutics Market, by Approach

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
8.3. Small Molecule Therapies
- 8.3.1. Global Human Microbiome Therapeutics Market, by Small Molecule Therapies, by Region, 2020-2034 (USD Billion)
8.4. Single Strain Whole Bacteria
- 8.4.1. Global Human Microbiome Therapeutics Market, by Single Strain Whole Bacteria, by Region, 2020-2034 (USD Billion)
8.5. Microbial Consortia
- 8.5.1. Global Human Microbiome Therapeutics Market, by Microbial Consortia, by Region, 2020-2034 (USD Billion)
8.6. Genetically Modified Single Strain Bacteria
- 8.6.1. Global Human Microbiome Therapeutics Market, by Genetically Modified Single Strain Bacteria, by Region, 2020-2034 (USD Billion)
8.7. Phage Cocktail
- 8.7.1. Global Human Microbiome Therapeutics Market, by Phage Cocktail, by Region, 2020-2034 (USD Billion)
8.8. Microbial Ecosystems
- 8.8.1. Global Human Microbiome Therapeutics Market, by Microbial Ecosystems, by Region, 2020-2034 (USD Billion)

9. Global Human Microbiome Therapeutics Market, by Geography

9.1. Key Findings
9.2. Introduction
- 9.2.1. Human Microbiome Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
9.3. Human Microbiome Therapeutics Market - North America
- 9.3.1. North America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.3.2. North America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.3.3. North America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.3.4. North America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.3.5. Human Microbiome Therapeutics Market - US
  - 9.3.5.1. US: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.3.5.2. US: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.3.5.3. US: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.3.5.4. US: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.3.6. Human Microbiome Therapeutics Market - Canada
  - 9.3.6.1. Canada: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.3.6.2. Canada: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.3.6.3. Canada: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.3.6.4. Canada: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
9.4. Human Microbiome Therapeutics Market - Europe
- 9.4.1. Europe: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.4.2. Europe: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.4.3. Europe: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.4.4. Europe: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.5. Human Microbiome Therapeutics Market - UK
  - 9.4.5.1. UK: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.5.2. UK: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.5.3. UK: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.5.4. UK: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.6. Human Microbiome Therapeutics Market - France
  - 9.4.6.1. France: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.6.2. France: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.6.3. France: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.6.4. France: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.7. Human Microbiome Therapeutics Market - Germany
  - 9.4.7.1. Germany: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.7.2. Germany: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.7.3. Germany: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.7.4. Germany: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.8. Human Microbiome Therapeutics Market - Italy
  - 9.4.8.1. Italy: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.8.2. Italy: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.8.3. Italy: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.8.4. Italy: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.9. Human Microbiome Therapeutics Market - Spain
  - 9.4.9.1. Spain: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.9.2. Spain: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.9.3. Spain: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.9.4. Spain: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.10. Human Microbiome Therapeutics Market - Netherlands
  - 9.4.10.1. Netherlands: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.10.2. Netherlands: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.10.3. Netherlands: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.10.4. Netherlands: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.11. Human Microbiome Therapeutics Market - Russia
  - 9.4.11.1. Russia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.11.2. Russia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.11.3. Russia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.11.4. Russia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.4.12. Human Microbiome Therapeutics Market - Rest of Europe
  - 9.4.12.1. Rest of Europe: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.4.12.2. Rest of Europe: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.4.12.3. Rest of Europe: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.4.12.4. Rest of Europe: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
9.5. Human Microbiome Therapeutics Market - Asia Pacific
- 9.5.1. Asia Pacific: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.5. Human Microbiome Therapeutics Market - China
  - 9.5.5.1. China: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.5.2. China: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.5.3. China: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.5.4. China: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.6. Human Microbiome Therapeutics Market - India
  - 9.5.6.1. India: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.6.2. India: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.6.3. India: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.6.4. India: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.7. Human Microbiome Therapeutics Market - Malaysia
  - 9.5.7.1. Malaysia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.7.2. Malaysia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.7.3. Malaysia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.7.4. Malaysia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.8. Human Microbiome Therapeutics Market - Japan
  - 9.5.8.1. Japan: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.8.2. Japan: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.8.3. Japan: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.8.4. Japan: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.9. Human Microbiome Therapeutics Market - Indonesia
  - 9.5.9.1. Indonesia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.9.2. Indonesia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.9.3. Indonesia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.9.4. Indonesia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.10. Human Microbiome Therapeutics Market - South Korea
  - 9.5.10.1. South Korea: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.10.2. South Korea: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.10.3. South Korea: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.10.4. South Korea: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.11. Human Microbiome Therapeutics Market - Australia
  - 9.5.11.1. Australia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.11.2. Australia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.11.3. Australia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.11.4. Australia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.5.12. Human Microbiome Therapeutics Market - Rest of Asia Pacific
  - 9.5.12.1. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.5.12.2. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.5.12.3. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.5.12.4. Rest of Asia Pacific: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
9.6. Human Microbiome Therapeutics Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.5. Human Microbiome Therapeutics Market - Saudi Arabia
  - 9.6.5.1. Saudi Arabia: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.6.5.2. Saudi Arabia: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.6.5.3. Saudi Arabia: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.6.5.4. Saudi Arabia: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.6. Human Microbiome Therapeutics Market - UAE
  - 9.6.6.1. UAE: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.6.6.2. UAE: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.6.6.3. UAE: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.6.6.4. UAE: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.7. Human Microbiome Therapeutics Market - Israel
  - 9.6.7.1. Israel: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.6.7.2. Israel: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.6.7.3. Israel: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.6.7.4. Israel: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.8. Human Microbiome Therapeutics Market - South Africa
  - 9.6.8.1. South Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.6.8.2. South Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.6.8.3. South Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.6.8.4. South Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.6.9. Human Microbiome Therapeutics Market - Rest of Middle East & Africa
  - 9.6.9.1. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.6.9.2. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.6.9.3. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.6.9.4. Rest of Middle East & Africa: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
9.7. Human Microbiome Therapeutics Market - Latin America
- 9.7.1. Latin America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.5. Human Microbiome Therapeutics Market - Mexico
  - 9.7.5.1. Mexico: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.7.5.2. Mexico: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.7.5.3. Mexico: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.7.5.4. Mexico: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.6. Human Microbiome Therapeutics Market - Brazil
  - 9.7.6.1. Brazil: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.7.6.2. Brazil: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.7.6.3. Brazil: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.7.6.4. Brazil: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.7. Human Microbiome Therapeutics Market - Argentina
  - 9.7.7.1. Argentina: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.7.7.2. Argentina: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.7.7.3. Argentina: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.7.7.4. Argentina: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)
- 9.7.8. Human Microbiome Therapeutics Market - Rest of Latin America
  - 9.7.8.1. Rest of Latin America: Human Microbiome Therapeutics Market, by Product, 2020-2034 (USD Billion)
  - 9.7.8.2. Rest of Latin America: Human Microbiome Therapeutics Market, by Therapeutic Area, 2020-2034 (USD Billion)
  - 9.7.8.3. Rest of Latin America: Human Microbiome Therapeutics Market, by Indication, 2020-2034 (USD Billion)
  - 9.7.8.4. Rest of Latin America: Human Microbiome Therapeutics Market, by Approach, 2020-2034 (USD Billion)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. Enterome Sa
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Ferring Pharmaceuticals
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Finch Therapeutics Group Inc.
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Locus Biosciences Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Maat Pharma
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. Microbiotica Ltd
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Osel Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Seres Therapeutics Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Synlogic Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Vedanta Biosciences
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development